TDMS Study 05024-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
N-METHYLOLACRYLAMIDE
NTP Experiment-Test: 05024-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/04/94
Route: GAVAGE Time: 03:20:15
Facility: Battelle Columbus Laboratory
Chemical CAS #: 924-42-5
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 10 20 12
Dead 5 8 5
Survivors
Terminal Sacrifice 35 22 33
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (49) (16) (50)
Intestine Small, Ileum (46) (16) (48)
Intestine Small, Jejunum (48) (16) (48)
Liver (50) (21) (50)
Mesentery (49) (18) (49)
Pancreas (50) (17) (50)
Salivary Glands (50) (16) (50)
Stomach, Forestomach (49) (16) (50)
Squamous Cell Papilloma 1 (6%)
Stomach, Glandular (49) (16) (50)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (16) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Adenoma 3 (6%) 1 (2%) 1 (2%)
Adrenal Gland, Medulla (50) (50) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%) 2 (4%)
Islets, Pancreatic (50) (16) (50)
Adenoma 2 (4%)
Parathyroid Gland (34) (15) (42)
Adenoma 1 (2%)
Pituitary Gland (49) (40) (50)
Pars Distalis, Adenoma 19 (39%) 19 (48%) 14 (28%)
Thyroid Gland (50) (17) (50)
C-Cell, Adenoma 11 (22%) 2 (12%) 7 (14%)
Page 2
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (45) (17) (50)
Adenoma 2 (4%) 2 (12%) 4 (8%)
Ovary (50) (20) (50)
Granulosa Cell Tumor Benign 1 (2%)
Uterus (50) (19) (50)
Polyp 1 (2%) 1 (2%)
Polyp Stromal 6 (12%) 2 (11%) 6 (12%)
Polyp Stromal, Multiple 1 (2%) 2 (4%)
Sarcoma Stromal 3 (16%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (16) (50)
Lymph Node (50) (21) (50)
Lymph Node, Mesenteric (3) (4) (6)
Spleen (50) (22) (50)
Thymus (38) (16) (41)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (24) (50)
Adenocarcinoma 1 (2%) 1 (4%) 1 (2%)
Fibroadenoma 15 (31%) 9 (38%) 13 (26%)
Fibroadenoma, Multiple 4 (8%) 4 (8%)
Skin (50) (24) (50)
Trichoepithelioma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (4%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (4%)
Subcutaneous Tissue, Myxoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (16) (50)
Cranium, Osteosarcoma 1 (6%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Spinal Cord (50) (16) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (17) (50)
Alveolar/Bronchiolar Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1)
Carcinoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (17) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia Mononuclear 14 (28%) 11 (22%) 15 (30%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 4
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 36 42
Total Primary Neoplasms 86 56 78
Total Animals with Benign Neoplasms 39 28 36
Total Benign Neoplasms 68 38 60
Total Animals with Malignant Neoplasms 18 16 18
Total Malignant Neoplasms 18 18 18
Total Animals with Metastatic Neoplasms
Total Metastatic Neoplasm
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 5
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 15 21 19
Dead 7 7 4
Survivors
Terminal Sacrifice 28 21 27
Moribund 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (49) (14) (50)
Intestine Large, Rectum (49) (15) (49)
Intestine Small, Ileum (48) (14) (50)
Intestine Small, Jejunum (49) (14) (50)
Liver (50) (50) (50)
Hepatocellular Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Neoplastic Nodule 4 (8%) 1 (2%)
Mesentery (47) (16) (50)
Lipoma 1 (2%)
Pancreas (50) (17) (50)
Salivary Glands (50) (15) (49)
Stomach, Forestomach (50) (15) (50)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (14) (50)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
Tooth (49) (16) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (21) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Adenoma 2 (4%) 1 (2%)
Adrenal Gland, Medulla (49) (50) (50)
Pheochromocytoma Malignant 2 (4%) 2 (4%)
Pheochromocytoma Benign 10 (20%) 7 (14%) 11 (22%)
Page 6
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Bilateral, Pheochromocytoma Benign 8 (16%) 2 (4%)
Islets, Pancreatic (50) (14) (50)
Adenoma 2 (4%)
Parathyroid Gland (48) (14) (45)
Adenoma 1 (2%)
Pituitary Gland (50) (23) (50)
Pars Distalis, Adenoma 18 (36%) 14 (61%) 13 (26%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (50) (17) (50)
C-Cell, Adenoma 7 (14%) 4 (24%) 9 (18%)
C-Cell, Carcinoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (16) (49)
Preputial Gland (49) (17) (48)
Adenoma 2 (4%) 2 (12%) 3 (6%)
Squamous Cell Carcinoma 1 (6%)
Prostate (50) (19) (49)
Testes (50) (48) (50)
Bilateral, Interstitial Cell, Adenoma 33 (66%) 33 (69%) 38 (76%)
Interstitial Cell, Adenoma 7 (14%) 8 (17%) 8 (16%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (1) (2)
Bone Marrow (50) (16) (50)
Femoral, Vertebral, Histiocytic Sarcoma 1 (2%)
Lymph Node (50) (25) (50)
Mediastinal, Carcinosarcoma, Metastatic, Lung 1 (2%)
Lymph Node, Mesenteric (15) (6) (8)
Spleen (50) (47) (50)
Hemangioma 1 (2%)
Sarcoma 1 (2%)
Thymus (37) (14) (35)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (37) (15) (39)
Adenocarcinoma 1 (3%)
Adenoma 1 (3%)
Fibroadenoma 2 (5%) 1 (7%) 1 (3%)
Skin (50) (25) (50)
Basal Cell Adenoma 1 (2%) 1 (4%) 1 (2%)
Basosquamous Tumor Benign 1 (2%)
Keratoacanthoma 1 (2%) 6 (24%) 3 (6%)
Squamous Cell Papilloma 1 (2%) 2 (8%)
Sebaceous Gland, Adenoma 1 (2%) 1 (4%) 1 (2%)
Subcutaneous Tissue, Fibroma 3 (6%) 1 (4%) 2 (4%)
Subcutaneous Tissue, Fibroma, Multiple 1 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (50) (16) (50)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (48) (16) (50)
Astrocytoma Malignant 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Glioma Malignant 1 (6%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (17) (49)
Alveolar/Bronchiolar Adenoma 1 (2%)
Carcinosarcoma 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
Nose (50) (16) (50)
Nasolacrimal Duct, Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1)
Adenoma 1 (100%)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (36) (50)
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
Urinary Bladder (50) (18) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 18 (36%) 18 (36%) 24 (48%)
Mesothelioma Malignant 1 (2%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05024-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 03:20:15
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 6 MG/KG 12 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 49 49
Total Primary Neoplasms 131 109 129
Total Animals with Benign Neoplasms 48 48 49
Total Benign Neoplasms 105 84 98
Total Animals with Malignant Neoplasms 23 23 29
Total Malignant Neoplasms 26 25 31
Total Animals with Metastatic Neoplasms 3 1
Total Metastatic Neoplasm 3 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 57283-57283/57283
--multipart-boundary--